EcoDrugPlus

Activin A Receptor Type 2b

Ensembl ID : ENSLCAG00010022940
Gene Symbol: ACVR2B
4 Cross references
195 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSLCAG00010020207
Gene Symbol: ACVR2BA
4 Cross references
193 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSLCAG00010011799
Gene Symbol: ADORA1
4 Cross references
204 Possible Orthologues:

Adenosine A1 Receptor B

Ensembl ID : ENSLCAG00010006710
Gene Symbol: ADORA1B
4 Cross references
173 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSLCAG00010005230
Gene Symbol: ADORA2A
4 Cross references
198 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSLCAG00010027946
Gene Symbol: ADORA2AA
4 Cross references
189 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSLCAG00010019387
Gene Symbol: LOC108893222
4 Cross references
199 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSLCAG00010015433
Gene Symbol: ADORA3
1 Cross references
144 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSLCAG00010005397
Gene Symbol: ADORA3
1 Cross references
144 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSLCAG00010009138
Gene Symbol: ADA
1 Cross references
216 Possible Orthologues:

Adrenoceptor Alpha 1aa

Ensembl ID : ENSLCAG00010026671
Gene Symbol: ADRA1AA
4 Cross references
202 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSLCAG00010019502
Gene Symbol: ADRA1B
1 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).